Lymphoma Medication: From Chemo to Targeted Therapies

Lymphoma medication spans a wide and growing range of drug classes, from traditional chemotherapy to engineered immune cells that hunt cancer on their own. Which drugs a person receives depends heavily on the lymphoma subtype, the stage of disease, and whether it has come back after prior treatment. Over the past two decades, the addition of targeted therapies and immunotherapies to older chemotherapy backbones has reshaped outcomes for many patients, though challenges like drug resistance and treatment costs remain serious concerns.

Chemotherapy and Rituximab as the Standard Foundation

For the most common aggressive form, diffuse large B-cell lymphoma (DLBCL), the go-to first-line regimen is R-CHOP: rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. This combination cures a meaningful share of patients, but roughly 30 to 50 percent are not cured by it, depending on disease stage and risk factors. Among those who fail R-CHOP, about 20 percent have primary refractory disease, meaning the cancer never truly responds or grows back during treatment, while another 30 percent relapse after initially achieving a complete response.¹ Those numbers matter because they frame everything else in the treatment landscape: the newer drug classes discussed below exist largely to help patients for whom chemotherapy alone falls short.

For slower-growing (indolent) lymphomas like follicular lymphoma, the initial chemotherapy backbone may differ, but rituximab still plays a central role. The recognition that different lymphoma subtypes behave as biologically distinct diseases, each with its own relapse patterns and drug sensitivities, has driven the shift toward subtype-specific treatment strategies.²

How Rituximab Changed the Game

Rituximab is a monoclonal antibody, essentially a lab-made protein designed to latch onto CD20, a molecule found on the surface of most B-cell lymphomas. Once it binds, it kills cancer cells through several mechanisms at once: it flags the cell for destruction by the immune system, activates a cascade of blood proteins called complement that punch holes in the cell membrane, and can trigger the cell’s own self-destruct program.³ The drug also appears to sensitize cancer cells to chemotherapy, making the two more effective together than either would be alone.⁴

Among these killing pathways, complement activation and immune-cell-mediated destruction are considered the two heaviest hitters, though which mechanism matters most can vary by patient and tumor.⁵ Rituximab’s success paved the way for a broader principle in lymphoma treatment: if you can find a reliable molecular target on the surface of cancer cells, you can build a drug to exploit it.

Drugs That Block Cancer Cell Survival Signals

Many B-cell lymphomas depend on internal signaling pathways to stay alive and keep dividing. Several newer drug classes work by jamming those signals.

BTK Inhibitors

Ibrutinib was the first approved drug in this class. It permanently attaches to Bruton’s tyrosine kinase (BTK), a protein that sits downstream of the B-cell receptor and is critical for B-cell survival. By shutting BTK down, ibrutinib blocks the signaling that keeps malignant B cells activated and growing, pushing them toward cell death.⁶ Ibrutinib and its successors, acalabrutinib and zanubrutinib, are used across several lymphoma types, including mantle cell lymphoma, marginal zone lymphoma, and some cases of chronic lymphocytic leukemia that overlap with lymphoma.

The limitation is that cancers can develop resistance. Mutations in BTK or activation of bypass signaling pathways can let lymphoma cells survive even while BTK is blocked.⁷ To address this, a newer generation of non-covalent BTK inhibitors has emerged. Pirtobrutinib, now FDA-approved for relapsed mantle cell lymphoma, binds to BTK in a reversible way that can still work against some of the mutations that defeat ibrutinib.⁸

BCL-2 Inhibitors

Venetoclax targets a different survival mechanism. Many lymphoma cells overproduce a protein called BCL-2, which acts like a shield against programmed cell death. Venetoclax mimics the natural “death signal” molecule that would normally neutralize BCL-2, effectively removing the shield and allowing the cancer cell to self-destruct. In DLBCL, venetoclax has shown potent effects, though resistance can develop when cancer cells ramp up alternative anti-death proteins to compensate.⁹ Researchers are testing combination strategies, like pairing venetoclax with drugs called HDAC inhibitors, to overcome that resistance. Experimental agents targeting BCL-2 through a different binding site are also in development for cases where venetoclax stops working.¹⁰

EZH2 Inhibitors

Some follicular lymphomas are driven by changes in how genes are switched on and off, rather than by mutations in the genes themselves. One key player is EZH2, an enzyme that silences genes. When EZH2 is overactive, it keeps B cells locked in a growth-friendly state and prevents them from maturing normally. Tazemetostat, the first FDA-approved EZH2 inhibitor (approved in 2020), blocks this enzyme in both its normal and mutated forms. In trials, about 69 percent of patients whose tumors carried an EZH2 mutation responded, along with 35 percent of those without the mutation.¹¹

An intriguing recent finding is that tazemetostat may also help the immune system recognize lymphoma cells better. In laboratory studies, pretreating lymphoma cells with the drug improved how well T cells could find and kill them, with longer contact times and larger interaction surfaces between the two cell types.¹² This suggests EZH2 inhibitors could eventually be combined with immunotherapies for a stronger effect.

Immunotherapy Approaches

Beyond rituximab, several immunotherapy strategies have entered the lymphoma toolkit, each harnessing the immune system in a different way.

CAR T-Cell Therapy

In this approach, a patient’s own T cells are collected, genetically modified in a lab to recognize the CD19 protein on lymphoma cells, and infused back into the patient. The results in relapsed or refractory B-cell lymphomas have been striking enough that the FDA approved three CD19-targeting CAR T products for lymphoma, initially in the third-line setting and later for second-line use after follow-up trials.¹³ For patients who had run out of conventional options, CAR T-cell therapy offered unprecedented response rates and durable remissions.¹⁴

CAR T is not without complications. The two major side effects are cytokine release syndrome (CRS), an inflammatory storm caused by mass activation of the engineered T cells, and neurotoxicity. Guidelines recommend treating severe CRS with tocilizumab, an anti-inflammatory drug, with or without corticosteroids. Neurotoxicity is managed primarily with corticosteroids and supportive care, and patients can decline rapidly, so close monitoring matters.¹⁵

Resistance to CAR T therapy can also occur. In some cases, the lymphoma cells develop mutations in CD19 itself, changing the protein’s shape so the engineered T cells can no longer recognize it. Researchers have identified alternative CAR designs that can still target these mutated versions of CD19, offering a potential workaround.¹⁶

Checkpoint Inhibitors

Classical Hodgkin lymphoma is a special case in the immunotherapy story. The malignant Reed-Sternberg cells in Hodgkin lymphoma frequently carry genetic changes on chromosome 9p24.1 that cause them to overexpress PD-L1, a molecule that tells the immune system to stand down. By displaying this “do not attack” signal, the cancer effectively hides from T cells.¹⁷ Checkpoint inhibitors like pembrolizumab and nivolumab block this interaction, releasing the brakes on T cells so they can attack the tumor. Response rates in Hodgkin lymphoma are among the highest seen with checkpoint blockade in any cancer, precisely because of how consistently these tumors overexpress PD-L1.¹⁸ In most non-Hodgkin lymphomas, checkpoint inhibitors have been less impressive on their own, though combination strategies continue to be explored.

Bispecific Antibodies and Antibody-Drug Conjugates

Bispecific antibodies are engineered proteins with two binding arms: one grabs a tumor cell (usually via CD20 or another surface protein), and the other grabs a T cell. By physically bridging the two, the antibody forces a close encounter that activates the T cell to kill the cancer cell, without needing the traditional immune-recognition machinery.¹⁹ Several bispecific antibodies have gained approval for B-cell lymphomas in recent years, filling an important niche for patients who relapse after earlier lines of therapy.

Antibody-drug conjugates (ADCs) take a different approach: they attach a potent chemotherapy payload to an antibody that targets a specific protein on lymphoma cells. Brentuximab vedotin, the best-established ADC in lymphoma, targets CD30, a protein found on Reed-Sternberg cells and certain other lymphoma types. It delivers its toxic payload directly into the cancer cell after binding, sparing most healthy tissue. A decade of clinical use has demonstrated sustained benefits across a range of CD30-positive lymphomas.²⁰ Newer ADCs targeting different proteins are entering the field as well.

Maintenance Therapy After the Initial Course

For follicular lymphoma, treatment does not always end when chemotherapy finishes. The PRIMA trial, one of the largest studies in this space, showed that continuing rituximab as maintenance therapy for two years after initial immunochemotherapy nearly doubled the time before the disease progressed. Median progression-free survival was about 10.5 years with maintenance rituximab compared to 4.1 years with observation alone.²¹ That is a large difference in how long patients remain disease-free.

An important caveat: this maintenance approach did not improve overall survival, with roughly 80 percent of patients in both groups alive at 10 years. Patients in the observation group who relapsed often responded well to subsequent treatment, which may partly explain why survival rates converged. The trade-off is real, though: maintenance rituximab comes with higher rates of grade 3-4 adverse events and infections. In the initial report, infections (grade 2 or higher) occurred in about 39 percent of patients on maintenance versus 24 percent in the observation group.²² The decision to pursue maintenance involves weighing a longer disease-free period against a higher burden of side effects.

Radioimmunotherapy

A less commonly discussed class of lymphoma medication attaches radioactive isotopes to monoclonal antibodies. The antibody guides the radiation directly to lymphoma cells, delivering localized damage while limiting exposure to the rest of the body. Ibritumomab tiuxetan, which carries yttrium-90 attached to a CD20-targeting antibody, was approved by the FDA for relapsed or refractory follicular lymphoma.²³ The approach has shown promising results, particularly for patients whose disease has stopped responding to other treatments.²⁴ Despite its efficacy, radioimmunotherapy has been underused in practice, partly because of logistical challenges in handling radioactive materials and the rise of competing therapies.

Why Treating Children and Adolescents Differs

Pediatric lymphoma treatment looks superficially similar to adult treatment but carries distinct concerns. At the time of writing, no targeted agents like rituximab or brentuximab vedotin had gained regulatory approval specifically for use in pediatric lymphoma patients, though some are used off-label.²⁵ Pediatric protocols tend to use more intensive chemotherapy regimens, and adolescent and young adult patients treated at pediatric centers experienced more unplanned hospitalizations, febrile neutropenia, and severe mucositis compared to similar patients treated at adult centers, likely reflecting these more aggressive regimens.²⁶

Long-term side effects also weigh more heavily in pediatric decisions. Radiation therapy in children tends to involve larger treatment areas and leads to greater estimated years of life lost compared to adult protocols, even when the prescribed dose is lower.²⁷ This is why major pediatric Hodgkin lymphoma groups have spent decades studying strategies to reduce or eliminate radiation in children who respond well to chemotherapy.

The Cost Problem

Newer lymphoma medications, particularly CAR T-cell therapy, come with staggering price tags. A cost-effectiveness analysis estimated that treating all eligible patients with CAR T-cell therapy in the United States could add roughly $10 billion to health care spending over five years.²⁸ Medicare reimburses an average of about $498,700 per inpatient CAR T admission, which includes the product cost and the intensive monitoring needed for complications like CRS and neurotoxicity. In contrast, a typical week-long hospital stay costs Medicare only $13,000 to $18,000.²⁹

One strategy for reducing costs is outpatient CAR T administration, where patients receive their infusion and are monitored with shorter hospital stays. At least one community-based center has reported saving around $78,000 to $108,000 per patient using a six-day inpatient stay instead of the typical 15 days, without worse outcomes.³⁰ An analysis in China found that CAR T therapies were not cost-effective at currently available willingness-to-pay thresholds, with the authors concluding that price reductions are the main path to making the drugs proportional to their health benefits.³¹ Financial toxicity, the burden that treatment costs impose on patients and families, is increasingly recognized as a real side effect of cancer therapy in its own right.

Supportive Care During Treatment

Managing the side effects of lymphoma medication is its own discipline. One of the most common risks during chemotherapy is febrile neutropenia, a dangerous drop in white blood cells that leaves patients vulnerable to infections. For the R-CHOP regimen specifically, the overall risk of hospitalization for febrile neutropenia across six cycles is about 23 percent, with the greatest risk during the first two cycles. Patients who are 65 or older, have low baseline albumin levels, or have liver disease face higher risk.³² Preventive antibiotics with levofloxacin are not recommended for everyone on R-CHOP but can be appropriate for patients who carry multiple risk factors.

Growth factor injections to boost white blood cell counts, antiviral drugs to prevent reactivation of viruses like hepatitis B (a known risk with rituximab), and antifungal prophylaxis in certain settings round out the supportive care picture. The intensity of supportive care scales with the intensity of treatment: a patient on oral ibrutinib at home needs far less prophylaxis than someone undergoing CAR T-cell infusion in a hospital.

Blood-Based Monitoring and Where It Is Heading

A newer development that is changing how lymphoma medications are used is circulating tumor DNA (ctDNA) analysis, sometimes called a liquid biopsy. Instead of surgically removing a piece of tumor tissue, doctors draw a blood sample and analyze fragments of DNA shed by cancer cells. This approach captures the full genetic picture of the tumor rather than just a single site, and it can be repeated easily over time to track how the disease responds to treatment.³³

ctDNA levels can serve as a real-time readout of tumor burden. A rapid drop after starting therapy may signal a good response, while persistent or rising ctDNA can flag resistance before it shows up on a scan. The technology also has potential for diagnosis and risk stratification, helping identify upfront which patients may need more aggressive treatment.³⁴ As this tool matures, it could allow earlier switches between medications when one is failing, sparing patients weeks or months on an ineffective regimen. Early-stage research is even exploring whether ctDNA could one day help decide when it is safe to stop treatment in patients who appear to be in deep remission.

Reaching the Brain

One longstanding challenge in lymphoma treatment is central nervous system involvement. The blood-brain barrier, which protects the brain from toxins in the bloodstream, also blocks most lymphoma drugs from reaching tumors that have spread there. A proof-of-concept study recently tested polatuzumab vedotin, an antibody-drug conjugate approved for DLBCL, in both animal models and a small group of patients with CNS lymphoma. In mice, the drug reduced brain tumor burden and extended survival. In patients, cerebrospinal fluid concentrations reached levels above the drug’s effective threshold, at about 0.56 to 1.31 percent of blood levels, and two of three patients achieved a complete response.³⁵ These are very early data, but they suggest that the blood-brain barrier may not be as absolute a wall as once assumed for every drug class, opening a door that has been frustratingly closed for most lymphoma medications.